Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Induction immunosuppression.

Allan D Kirk

    Transplantation
    |September 14, 2006
    PubMed
    Summary
    This summary is machine-generated.

    Induction immunosuppression uses potent therapies to prevent early acute rejection after transplantation. While antibody therapies reduce acute rejection rates, their long-term transplant benefits require further investigation.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Self-Reported Flourishing Among U.S. Surgeons: A National Physician Survey.

    Journal of the American College of Surgeons·2026
    Same author

    American Journal of Transplantation at 25 years: A trusted voice.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
    Same author

    Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
    Same author

    A Report of Four Depletional Induction Strategies in Non-Human Primate Islet Xenotransplantation.

    Xenotransplantation·2026
    Same author

    Costimulatory blockade and infectious risk in solid organ transplantation.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
    Same author

    Corrigendum to "Antibodies to angiotensin II type 1 receptor and endothelin type A receptor are associated with cytokine production enriched for type 2 immune response and antibody production in pediatric kidney transplant recipients" [American Journal of Transplantation. Volume 25, Issue 11, November 2025, Pages 2329-2344].

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025
    Same journal

    Filtered or Fried? Rethinking Intraoperative Cell Salvage in Liver Transplantation.

    Transplantation·2026
    Same journal

    Simultaneous Liver-kidney Versus Liver Transplantation Categorized by Pretransplant eGFR: Impact of the 2017 OPTN Policy.

    Transplantation·2026
    Same journal

    Preformed Anti-DQ Alpha Donor-specific Antibodies and the Risk of Antibody-mediated Rejection After Kidney Transplantation.

    Transplantation·2026
    Same journal

    People in Transplantation: Professor Nadey Hakim, MD, PhD, FRCS, FRCSGlas (Hon), FACS, President-Elect of The Transplantation Society.

    Transplantation·2026
    Same journal

    IL-1 Receptor Blockade Modulates Inflammation During Sequential Perfusion in Ex Vivo Porcine Kidneys.

    Transplantation·2026
    Same journal

    Regulatory T Cells Allosensitized Under the Blockade of CD80/CD86-CD28 Costimulation Prolonged Islet Allograft Survival.

    Transplantation·2026
    See all related articles

    Area of Science:

    • Transplantation immunology
    • Immunosuppressive therapy

    Background:

    • Induction immunosuppression is a critical prophylactic strategy employed during organ transplantation.
    • It is based on the empirical need for intensified immunosuppression to prevent early acute rejection episodes.

    Discussion:

    • Recent trends favor specialized induction agents, particularly antibody therapies.
    • These agents effectively decrease acute rejection rates but lack proven long-term transplant outcome benefits.

    Key Insights:

    • The biological rationale and mechanisms of action for current induction agents are reviewed.
    • Clinical trial data on various induction regimens are critically evaluated.

    Outlook:

    • An individualized approach to selecting induction immunosuppressants is proposed.
  • Further research is needed to clarify the long-term impact of specialized induction therapies on transplant success.